Last month, the company said it has decided not to proceed with the Rs 4,000-crore capital infusion deal led by Carlyle as a legal battle will not be in the best interests of the company and its stakeholders.from Banking/Finance-Industry-Economic Times https://ift.tt/3bTfDVa
via IFTTT
No comments:
Post a Comment